Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202061 | 1.00 | MEN1 (0.42) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL13656955 | 1.00 | MEN1 (0.42) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL8853786 | 0.77 | ALDH1A1 (0.46) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL8853789 | 0.77 | ALDH1A1 (0.46) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL3324909 | 0.75 | GRIN2D (0.48) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL14011732 | 0.75 | CA12 (0.53) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL18424976 | 0.75 | KMT2A (0.44) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL19840166 | 0.75 | CA12 (0.53) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL2498832 | 0.75 | CA12 (0.53) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL18424973 | 0.75 | KMT2A (0.44) | MEN1NPC1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| US-8623519-B2 | Red phosphorescent compound and organic electroluminescent device using the same | LG DISPLAY CO., LTD. (KR) | 2014-01-07 | — | — | US | disclosed |
| US-7604683-B2 | Gas separation method using adsorbent | CANON KABUSHIKI KAISHA (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20070224450-A1 | Red phosphorescent compound and organic electroluminescent device using the same | LG DISPLAY CO., LTD. (KR) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | MEN1 324/4885NPC1 2922/4885MAPT 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.